Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.

Date publication

mars 2024

Journal

BMC gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola,Jahnsen J, Louis E, Lukáš M, Reinisch W, Roblin X, Smith PJ, Kwon T, Kim J, Yoon S, Kim DH, Atreya R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38539103

Résumé

While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn's disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable efficacy during maintenance treatment, comparative data specific to subcutaneous (SC) IFX (i.e., CT-P13 SC) versus VDZ are limited.

Mots clés

Biobetter, Bioinnovative, Inflammatory bowel disease, Subcutaneous infliximab, Tumour necrosis factor-α inhibitors, Vedolizumab

Référence

BMC Gastroenterol. 2024 03 27;24(1):121